Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

Adverum Biotechnologies, Inc. reports financial results for the quarter ended March 31, 2017.

We analyze the earnings along side the following peers of Adverum Biotechnologies, Inc. – Acceleron Pharma Inc (XLRN-US) that have also reported for this period.

Highlights

  • Summary numbers: Revenues of USD 0.46 million, Net Earnings of USD -16.10 million.
  • Year-on-year change in operating cash flow of 2.76% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings decline largely a result of non-operational activity, pretax margins improved from -5,808.30% to -3,487.23%.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31
Relevant Numbers (Quarterly)
Revenues (mil) 0.46 0.49 0.4 0.31 0.27
Revenue Growth (%YOY) 74.34 -49.17 -58.55 51.23 30.54
Earnings (mil) -16.1 -22.39 -14.3 -61.66 -15.39
Earnings Growth (%YOY) -4.59 -58.89 -1.54 -531.37 -61.87
Net Margin (%) -3484.63 -4588.93 -3620.51 -20084.69 -5808.3
EPS -0.38 -0.54 -0.35 -1.76 -0.57
Return on Equity (%) -30.89 -39.65 -23.64 -100.83 -24.92
Return on Assets (%) -28.21 -36.48 -21.96 -95.36 -23.81

Access our Ratings and Scores for Adverum Biotechnologies, Inc.

Market Share Versus Profits

Revenues History
Earnings History

ADVM-US‘s change in revenue this period compared to the same period last year of 74.34% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that ADVM-US is holding onto its market share. Also, for comparison purposes, revenues changed by -5.33% and earnings by 28.11% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

ADVM-US‘s change in operating cash flow of 2.76% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings

Margins

The company’s earnings decline is largely a result of non-operational activity. As a matter of fact, the company showed increases in operating (EBIT) and pretax margins. EBIT margins improved from -5,852.08% to -3,593.07% and pretax margins widened from -5,808.30% to -3,487.23%.

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Adverum Biotechnologies, Inc.

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich’s ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of ADVM-US.